Novartis Ag (NVS) Other financing activities (2009 - 2026)

Novartis Ag has reported Other financing activities for 18 years, with the latest figure at -$67.0 million in Q2 2026.

• Quarterly Other financing activities rose 68.84% year-over-year to -$67.0 million in Q2 2026, while the trailing twelve-month figure through Mar 2026 was -$148.0 million (down 223.33% YoY) and the FY2025 annual result came in at -$203.0 million, down 336.05% from the prior year.
• Other financing activities fell to -$67.0 million in Q2 2026 per NVS's latest filing, from $78.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $150.0 million in Q4 2023 and troughed at -$215.0 million in Q2 2025.
• A 5-year average of $3.0 million and a median of $22.5 million in 2022 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2022 and 2025: Other financing activities sank 2783.33% in 2022, then jumped 309.09% in 2025.
• Over 5 years, Other financing activities stood at -$161.0 million in 2022, then soared by 193.17% to $150.0 million in 2023, then plunged by 81.33% to $28.0 million in 2024, then plunged by 217.86% to -$33.0 million in 2025, then plunged by 103.03% to -$67.0 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered -$67.0 million, $78.0 million, and -$33.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.